Comparative Pharmacology
Head-to-head clinical analysis: GVS versus NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GVS versus NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE.
GVS vs NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GVS is not a recognized drug. No mechanism of action available.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Polymyxin B is a cationic detergent antibiotic that disrupts bacterial cell membrane integrity by interacting with phospholipids. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
1 mg IV bolus every 3 minutes up to 3 doses as needed for status epilepticus; max total dose 3 mg.
Instill 3 to 4 drops into the affected ear(s) 3 to 4 times daily. For otic suspension in adults.
None Documented
None Documented
Terminal half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Neomycin: 2-3 hours (in adults with normal renal function); may accumulate in renal impairment. Polymyxin B: 6-8 hours (prolonged in renal impairment: up to 36 hours). Hydrocortisone: 1.2-1.5 hours (terminal).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Neomycin: >90% unchanged in feces after oral administration; negligible renal excretion. Polymyxin B: 60% renal excretion of unchanged drug; remainder nonrenal. Hydrocortisone: primarily hepatic metabolism, <5% renal excretion unchanged.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic